

Lorenza Landi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8428150/lorenza-landi-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

1,279
citations

17
h-index

35
g-index

39
ext. papers

1,449
ext. citations

5.4
avg, IF

4.1
L-index

#	Paper	IF	Citations
34	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. <i>British Journal of Cancer</i> , 2015 , 112, 95-102	8.7	407
33	HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2013 , 108, 668-75	8.7	109
32	Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. <i>British Journal of Cancer</i> , 2012 , 107, 793-9	8.7	90
31	Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 4954-62	12.9	74
30	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. <i>BJU International</i> , 2011 , 108, E250-7	5.6	67
29	microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 14924-9	11.5	61
28	Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. <i>Drugs</i> , 2012 , 72 Suppl 1, 28-36	12.1	54
27	HER2 and lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 1219-28	3.5	50
26	MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 37-45.e4	3.8	41
25	Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. <i>Current Opinion in Oncology</i> , 2013 , 25, 130-6	4.2	29
24	The neuropilin 2 isoform NRP2b uniquely supports TGF β -mediated progression in lung cancer. <i>Science Signaling</i> , 2017 , 10,	8.8	28
23	Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. <i>Clinical Lung Cancer</i> , 2014 , 15, 411-417.e4	4.9	28
22	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , 2019 , 20, e186-e194	4.9	27
21	Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. <i>Journal of the American Geriatrics Society</i> , 2010 , 58, 986-8	5.6	23
20	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 176-87	5.4	22
19	Experience with erlotinib in the treatment of non-small cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2015 , 9, 146-63	4.9	19
18	Irreversible EGFR-TKIs: dreaming perfection. <i>Translational Lung Cancer Research</i> , 2013 , 2, 40-9	4.4	19

17	Protein kinase inhibitors to treat non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1203-13	4	16
16	Pharmacotherapy targeting the EGFR oncogene in NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2293-305	4	16
15	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2018 , 9, 17554-17563	3.3	16
14	Management of NSCLC: focus on crizotinib. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2587-97	4	13
13	MET deregulation in breast cancer. <i>Annals of Translational Medicine</i> , 2015 , 3, 181	3.2	12
12	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. <i>Drugs</i> , 2016 , 76, 831-40	12.1	11
11	Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. <i>Oncotarget</i> , 2019 , 10, 561-572	3.3	7
10	Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. <i>PLoS ONE</i> , 2015 , 10, e0125037	3.7	7
9	Deregulation in Lung Cancer: Right Time to Adopt an Orphan?. <i>Clinical Cancer Research</i> , 2018 , 24, 2470-2473	4.7	5
8	Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 203-14	3.8	5
7	MET overexpression and gene amplification in NSCLC: a clinical perspective. <i>Lung Cancer: Targets and Therapy</i> , 2013 , 4, 15-25	2.9	5
6	Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. <i>Translational Lung Cancer Research</i> , 2016 , 5, 579-587	4.4	5
5	Raising the bar in education: the Thoracic Academy experience. <i>Future Oncology</i> , 2018 , 14, 1-2	3.6	
4	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology.. <i>Translational Cancer Research</i> , 2019 , 8, S16-S22	0.3	
3	Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11056-11056	2.2	
2	MicroRNA signature to predict sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3521-3521	2.2	
1	Micro-RNA signature differences in lung adenocarcinoma with specific driver alterations.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11066-11066	2.2	